GREENWICH LIFESCIENCES, INC. Deferred Compensation Liability, Current and Noncurrent
GREENWICH LIFESCIENCES, INC. (GLSI) had Deferred Compensation Liability, Current and Noncurrent of $673.82 thousand as of 2026-03-31, per its 10-Q filed 2026-06-04.
Financial Statements › Balance Sheet › Liabilities
us-gaap:DeferredCompensationLiabilityCurrentAndNoncurrent · last filed 2026-06-04
- 2026-03-31: Deferred Compensation Liability, Current and Noncurrent $673.82K.
- 2025-12-31: Deferred Compensation Liability, Current and Noncurrent $673.82K.
- 2025-03-31: Deferred Compensation Liability, Current and Noncurrent $306.28K.
- 2024-12-31: Deferred Compensation Liability, Current and Noncurrent $306.28K.
| Period end | Deferred Compensation Liability, Current and Noncurrent |
|---|---|
| 2026-03-31 | $673.82K 10-Q · filed 2026-06-04 |
| 2025-12-31 | $673.82K 10-Q · filed 2026-06-04 |
| 2025-03-31 | $306.28K 10-Q · filed 2025-05-20 |
| 2024-12-31 | $306.28K 10-K · filed 2026-06-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |